CN103732236B - 用于生产痘苗病毒的方法和组合物 - Google Patents

用于生产痘苗病毒的方法和组合物 Download PDF

Info

Publication number
CN103732236B
CN103732236B CN201280038029.8A CN201280038029A CN103732236B CN 103732236 B CN103732236 B CN 103732236B CN 201280038029 A CN201280038029 A CN 201280038029A CN 103732236 B CN103732236 B CN 103732236B
Authority
CN
China
Prior art keywords
vaccinia virus
virus
cells
hela cells
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280038029.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103732236A (zh
Inventor
D·克恩
J·贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kirn David
Original Assignee
SILLAJEN BIOTHERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SILLAJEN BIOTHERAPEUTICS Inc filed Critical SILLAJEN BIOTHERAPEUTICS Inc
Publication of CN103732236A publication Critical patent/CN103732236A/zh
Application granted granted Critical
Publication of CN103732236B publication Critical patent/CN103732236B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201280038029.8A 2011-08-05 2012-08-03 用于生产痘苗病毒的方法和组合物 Active CN103732236B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515724P 2011-08-05 2011-08-05
US61/515,724 2011-08-05
PCT/US2012/049550 WO2013022764A1 (en) 2011-08-05 2012-08-03 Methods and compositions for production of vaccina virus

Publications (2)

Publication Number Publication Date
CN103732236A CN103732236A (zh) 2014-04-16
CN103732236B true CN103732236B (zh) 2017-09-15

Family

ID=46650950

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280038029.8A Active CN103732236B (zh) 2011-08-05 2012-08-03 用于生产痘苗病毒的方法和组合物

Country Status (12)

Country Link
US (3) US9719105B2 (enExample)
EP (1) EP2739293B1 (enExample)
JP (1) JP6243333B2 (enExample)
KR (1) KR102022952B1 (enExample)
CN (1) CN103732236B (enExample)
AU (1) AU2012294606B2 (enExample)
BR (1) BR112014000787B1 (enExample)
CA (1) CA2841831C (enExample)
DK (1) DK2739293T3 (enExample)
ES (1) ES2813413T3 (enExample)
PL (1) PL2739293T3 (enExample)
WO (1) WO2013022764A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909957T3 (es) 2014-07-16 2022-05-11 Transgene Virus oncolítico para la expresión de moduladores de puntos de control inmunitarios
CN107949397A (zh) 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 免疫治疗疫苗和抗体组合治疗
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
ES2795010T3 (es) 2015-06-19 2020-11-20 Sillajen Inc Composiciones y métodos para la embolización viral
CN106676071B (zh) * 2015-11-06 2019-07-19 天士力创世杰（天津）生物制药有限公司 HeLa-F细胞及其用途
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
AU2017387549B2 (en) 2016-12-28 2023-07-06 Transgene Sa Oncolytic viruses and therapeutic molecules
JP7718815B2 (ja) 2017-04-21 2025-08-05 シルラゼン， インコーポレイテッド 腫瘍溶解性ワクシニアウイルスおよびチェックポイント阻害剤の併用療法
AU2018287159B2 (en) 2017-06-21 2025-01-16 Transgene Personalized vaccine
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CA3081436A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
EP3884044A4 (en) * 2018-11-21 2022-08-31 Western Oncolytics Ltd. MANUFACTURE OF VIRUSES
MX2021007860A (es) 2018-12-28 2021-10-26 Transgene Poxvirux deficiente en m2.
KR102228267B1 (ko) 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
CN112143693B (zh) * 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
EP4170023A4 (en) * 2020-06-22 2024-09-11 Kolon Life Science, Inc. METHOD FOR MASS PRODUCTION OF VACCINIA VIRUS USING SUSPENSION CELLS
US20230256057A1 (en) 2020-07-13 2023-08-17 Transgene Treatment of immune depression
TW202227621A (zh) 2020-11-19 2022-07-16 美商凱立凡爾免疫治療股份有限公司 重塑腫瘤微環境的溶瘤免疫療法
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2022232375A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
CN114395538A (zh) * 2022-01-19 2022-04-26 和元生物技术（上海）股份有限公司 一种促进重组病毒载体向细胞外分泌的方法
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
AU2023326730A1 (en) 2022-08-18 2025-03-13 Transgene Chimeric poxviruses
AU2024236322A1 (en) * 2023-03-10 2025-08-21 Bavarian Nordic A/S Methods of isolating poxviruses from avian cell cultures

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
WO2008113078A1 (en) * 2007-03-15 2008-09-18 Jennerex, Inc. Oncolytic vaccinia virus cancer therapy
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US20100279386A1 (en) * 2000-11-23 2010-11-04 Bavarian Nordic A/S Modified vaccinia ankara virus variant and cultivation method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
UA76731C2 (uk) * 2000-11-23 2006-09-15 Баваріан Нордік А/С Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації
KR101170653B1 (ko) 2002-08-12 2012-08-03 제네렉스, 인코포레이티드 폭스바이러스 및 암과 관련된 방법 및 조성물
ATE412737T1 (de) * 2005-04-11 2008-11-15 Crucell Holland Bv Virusreinigung mit ultrafiltration
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
CN101557824B (zh) * 2006-08-07 2012-01-25 财团法人化学及血清疗法研究所 活牛痘疫苗的制备方法
US8003364B2 (en) * 2007-05-14 2011-08-23 Bavarian Nordic A/S Purification of vaccinia viruses using hydrophobic interaction chromatography
WO2009048769A2 (en) * 2007-10-10 2009-04-16 Kirin Pharma Kabushiki Kaisha Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
WO2011017050A1 (en) 2009-07-28 2011-02-10 Corning Incorporated Synthetic microcarriers for culturing cells
US8747837B2 (en) * 2009-09-14 2014-06-10 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) * 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
US20100279386A1 (en) * 2000-11-23 2010-11-04 Bavarian Nordic A/S Modified vaccinia ankara virus variant and cultivation method
WO2008113078A1 (en) * 2007-03-15 2008-09-18 Jennerex, Inc. Oncolytic vaccinia virus cancer therapy
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma;A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Tar;《Molecular Therapy》;20110719;第19卷(第10期);第1913-1922 *
Comparative Proteomics of Human Monkeypox and Vaccinia Intracellular Mature and Extracellular Enveloped Virions;Nathan P. Manes等;《Journal of proteome research》;20080301;第7卷(第3期);第960-968页 *
Exploring Vaccinia Virus as a Tool for Large-Scale Recombinant Protein Expression;Nicole A. Bleckwenn等;《Biotechnol. Prog.》;20031231;第19卷(第1期);第130-136页 *
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF;J. H. Kim等;《Molecular therapy》;20060812;第14卷(第3期);第361-370页 *

Also Published As

Publication number Publication date
ES2813413T3 (es) 2021-03-23
US20170298324A1 (en) 2017-10-19
AU2012294606A1 (en) 2014-01-23
US10767166B2 (en) 2020-09-08
JP2014521353A (ja) 2014-08-28
CA2841831A1 (en) 2013-02-14
BR112014000787B1 (pt) 2021-04-13
WO2013022764A1 (en) 2013-02-14
KR20140058601A (ko) 2014-05-14
CA2841831C (en) 2019-12-31
EP2739293A1 (en) 2014-06-11
JP6243333B2 (ja) 2017-12-06
US20140162342A1 (en) 2014-06-12
US20190169578A1 (en) 2019-06-06
AU2012294606B2 (en) 2016-10-06
EP2739293B1 (en) 2020-06-10
KR102022952B1 (ko) 2019-09-20
CN103732236A (zh) 2014-04-16
BR112014000787A2 (pt) 2017-07-11
US9719105B2 (en) 2017-08-01
PL2739293T3 (pl) 2020-11-16
US10202581B2 (en) 2019-02-12
DK2739293T3 (da) 2020-08-24

Similar Documents

Publication Publication Date Title
CN103732236B (zh) 用于生产痘苗病毒的方法和组合物
RU2489486C2 (ru) Процесс получения поксвирусов и композиции поксвирусов
Ungerechts et al. Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
JP5855564B2 (ja) オルソポックスウイルスの製造および精製方法
US10087423B2 (en) Method for harvesting expression products
CN105189739A (zh) 生产腺病毒的方法
JP2012533311A (ja) ニワトリ胚消化のための酵素組成物
Grein et al. Screening different host cell lines for the dynamic production of measles virus
Léon et al. The EB66® cell line as a valuable cell substrate for MVA-based vaccines production
Jordan et al. A chemically defined production process for highly attenuated poxviruses
JP2015535687A (ja) 新規ｍｖａウイルス及びその使用
JP2022539511A (ja) ウイルスの生産方法及び採取用溶液組成物
Wolff et al. Capturing of cell culture‐derived modified Vaccinia Ankara virus by ion exchange and pseudo‐affinity membrane adsorbers
Fernandes et al. Upstream bioprocess for adenovirus vectors
HK1194296B (en) Methods and compositions for production of vaccina virus
HK1194296A (en) Methods and compositions for production of vaccina virus
Lothert Steric exclusion chromatography: Advancement of a laboratory-based platform technology into a key component of viral vector and vaccine production processes
Gilbert et al. Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: implication for vaccine development
Ferraz Bioprocess intensification for production of cell-based vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American California

Applicant after: Hilakin biological therapy Limited by Share Ltd

Address before: American California

Applicant before: Jennerex, Inc.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: JENNEREX BIOTHERAPEUTICS ULC TO: XILAJIN BIOLOGICAL TREATMENT CO., LTD.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194296

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: SILLAJEN INC.

Free format text: FORMER OWNER: XILAJIN BIOLOGICAL TREATMENT CO., LTD.

Effective date: 20150213

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150213

Address after: Busan

Applicant after: Kirn David

Address before: American California

Applicant before: Hilakin biological therapy Limited by Share Ltd

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1194296

Country of ref document: HK